immatics biotechnologies GmbH

immatics biotechnologies GmbH

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.

immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.

Our transformative product candidates are - best in class - Adoptive Cell Therapies and Bispecific TCR molecules TCER®. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology.

Our mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients.

Quick Facts:

150 Team members >100 Targets covering 20 major solid and liquid tumors About 80% of discovered targets are novel 2 proprietary technology platforms 8 proprietary development programs, thereof 3 in the clinic Multiple partnered programs Raised more than $230m in cash in five financings

Category

Biotechnology

Activity Biotechnology, Development, Life Science, Oncology, Pharmacy

Management

Harpreet Singh, Ph.D. - Chief Executive Officer
Carsten Reinhardt, M.D. Ph.D. - Managing Director and Chief Medical Officer
Rainer Kramer, Ph.D. - Managing Director and Chief Business Officer
Thomas Ulmer - Managing Director and Chief Financial Officer
Toni Weinschenk, Ph.D. - Chief Technology Officer
Cedrik Britten, M.D. - Chief Medical Officer
Stephen Eck, M.D. Ph.D. - Chief Medical Officer, Immatics US, Inc.
Steffen Walter, Ph.D. - Chief Scientific Officer, Immatics US, Inc.

Year of foundation

2000

Employees

150

Supervisory board

Peter Chambré (Chairman of the Board)
Friedrich von Bohlen und Halbach, Ph.D.
Christof Hettich, L.L.D.
Matthias Kromayer, Ph.D.
Erich Schlick, M.D. Wellington Partners
Harald F. Stock, Ph.D.

Academic board

Hans-Georg Rammensee, Ph.D. - Eberhard Karls University, Germany, (Vorsitzender)
Prof. Christoph Huber, Ph.D. - Johannes Gutenberg University, Germany Cornelius Melief, M.D. - Leiden University, The Netherlands
Cornelius Melief, M.D. - Leiden University, The Netherlands
Pedro Romero, M.D. - University of Lausanne, Switzerland
Patrick Hwu, M.D. - MD Anderson Cancer Center, Co-founder and SAB Chairman of Immatics US, Inc.
Cassian Yee, M.D. - MD Anderson Cancer Center, Co-founder of Immatics US, Inc.

News

02.07.2020

Immatics Announces Completion of Business Combination and Listing on NASDAQ

  • The business combination transaction with Arya Sciences Acquisition Corporation, a special purpose acquisition company sponsored by Perceptive Advisors, was completed on…
29.06.2020

Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics

New York, NY, Houston, TX and Tuebingen, Germany, June 29, 2020Arya Sciences Acquisition Corp. (NASDAQ: ARYA or “Arya”), a special purpose acquisition…

04.06.2020

Immatics Appoints Cedrik Britten as Chief Medical Officer

Former Head of Oncology Cell Therapy Research Unit at GSK to lead clinical development at Immatics

17.03.2020

Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapies

  • Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash held within Arya’s trust account
  • Leading…